Skip to main content Accessibility help
×
Home

Revitalizing monoamine oxidase inhibitors: a call for action

  • P. Ken Gillman (a1), S. Shalom Feinberg (a2) and Laura J. Fochtmann (a3)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Revitalizing monoamine oxidase inhibitors: a call for action
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Revitalizing monoamine oxidase inhibitors: a call for action
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Revitalizing monoamine oxidase inhibitors: a call for action
      Available formats
      ×

Abstract

  • An abstract is not available for this content so a preview has been provided below. To view the full text please use the links above to select your preferred format.

Copyright

Corresponding author

* Address correspondence to: Ken Gillman, PsychoTropical Research, PO Box 86, Rural View, Queensland 4740, Australia. (Email: ken.psychotropical@gmail.com)

References

Hide All
1. Ricken, R, Ulrich, S, Schlattmann, P, et al. Tranylcypromine in mind (part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017; 27(8): 714731.
2. Amsterdam, JD, Shults, J. MAOI efficacy and safety in advanced stage treatment-resistant depression–a retrospective study. J Affect Disord. 2005; 89(1–3): 183188.
3. Shulman, KI, Fischer, HD, Herrmann, N, et al. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009; 70(12): 16811686.
4. Birkenhager, TK, van den Broek, WW, Mulder, PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004; 65(11): 15051510.
5. Adli, M, Pilhatsch, M, Bauer, M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry. 2008; 41(6): 252257.
6. Razani, J, White, KL, White, J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry. 1983; 40(6): 657661.
7. Shulman, KI, Herrmann, N, Walker, SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013; 27(10): 789797.
8. Gillman, PK. A reassesment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna). 2018; 125(11): 17071717.
9. Gillman, PK. “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine. CNS Spectr. 2017; 22(5): 390.
10. Stahl, SM. Stahl’s Essential Psychopharmacology: The Prescribers Guide. 6th ed. New York, NY: Cambridge University Press; 2017.
11. Sackett, DL, Rosenberg, WM, Gray, JA, et al. Evidence based medicine: What it is and what it isn’t. BMJ. 1996; 312(7023): 7172.
12. Greenhalgh, T, Snow, R, Ryan, S, et al. Six ‘biases’ against patients and carers in evidence-based medicine. BMC Medicine. 2015; 13: 200.

Revitalizing monoamine oxidase inhibitors: a call for action

  • P. Ken Gillman (a1), S. Shalom Feinberg (a2) and Laura J. Fochtmann (a3)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed